Mundipharma Industry Breakfast Symposium
Speakers: Dr Brian Muller (Medical Affairs Director of Mundipharma) and Professor Nicholas Lintzeris (The Langton Centre)
Date: Saturday 2 March 2019
Session Time: 0730-0830
Venue/Room: Eureka Room 1, Melbourne Convention and Exhibition Centre
Title 1: NYXOID® – A new nasal spray formulation for opioid overdose
Mundipharma welcomed Therapeutic Goods Administration registration of NYXOID® in September 2018, as announced by Federal Health Minister Greg Hunt MP. Dr Brian Muller will discuss the availability of the first intranasal naloxone spray in Australia and share the pharmacokinetic properties of the ready-to-use, needle-free treatment for opioid overdose.
Title 2: Implementation and Evaluation of Take-Home Naloxone for Opioid Overdose Prevention in Emergency Department Settings: The ONE Study
Professor Nicholas Lintzeris is the Chief Investigator of The ONE Study (Overdose and take-home Naloxone in Emergency settings) which is a pilot study examining feasibility of delivering brief interventions addressing overdose prevention with ’Take Home Naloxone’ supply in ED settings. This is an open label pilot feasibility study examining the development and implementation of a brief intervention targeting overdose prevention with supply of take home supply of intranasal (IN) naloxone in 5 ED settings in NSW and Victoria, namely Prince of Wales Hospital (POWH), Royal Prince Alfred Hospital (RPAH), St Vincent’s Hospital in Sydney (SVHS); Calvary Mater Hospital (CMH) in Newcastle and St Vincent’s Hospital, Melbourne (SVHM).
Proudly supported by Mundipharma